7004 Stanhope Place
21 articles with Lakewood-Amedex Inc.
Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)
Lakewood-Amedex, Inc. announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU).
Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.
Lakewood-Amedex Inc. announced that Sumita Paul, MD, MPH, MBA has joined Lakewood-Amedex as Chief Medical Officer and Senior Vice President, Research and Development to lead its recently recruited scientific-clinical management team.
Lakewood-Amedex Receives Notice of Allowance for Two U.S. Patents Covering the Broad-Spectrum Antimicrobial Nu-8 Bisphosphocin®
Lakewood-Amedex Inc. announced that the U.S. Patent and Trademark Office has issued a "Notice of Allowance" for two broad patent applications related to the Company's broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled "Antimicrobial Compounds, Compositions, and Uses Thereof." The "Notice of Allowance" indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.
Lakewood-Amedex Prepares To Launch A Phase 2 cDFU Clinical Trial for Its Nu-3 Antimicrobial In The Bahamas
Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically applied Nu-3 antimicrobial used to eliminate infection and promote wound healing in patients with chronic diabetic foot ulcers (cDFU).
Mr. Evans-Freke is Co-Founder and Managing General Partner of Auven Therapeutics
Lakewood-Amedex Advances Bisphosphocin Nu-8 to IND-Enabling Studies to Treat Complicated Urinary Tract Infection
Lakewood-Amedex today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies.
Lakewood-Amedex Inc. Reports Positive Top-Line Data From Randomized Controlled Phase I/IIa Trial Of Nu-3 Antimicrobial In Patients With Infected Diabetic Foot Ulcers
Lakewood-Amedex Inc. Completes Clinical Trial Recruitment For Final Cohort Of The Company's Phase I/IIa Program In Patients With Infected Diabetic Foot Ulcers
Lakewood-Amedex Inc. Advances Novel Bisphosphocin Nu-8 Compound Based On Encouraging Pre-Clinical Results
Lakewood-Amedex Inc. Appoints Chief Medical Officer And Chief Scientific Officer To Enhance Drug Development And Clinical Trials Programs
Lakewood-Amedex Inc. Announces Its Novel Bisphospocin Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes
Lakewood-Amedex Inc. Announces Expanded Research Collaboration With The University Of Jyvaskyla Following Promising Results Demonstrating Bisphosphocin Activity Against Borrelia Burgdorferi
Lakewood-Amedex Inc. Submits Investigational New Drug Application For Bisphosphocin Nu-3 For The Treatment Of Diabetic Foot Infections
Lakewood-Amedex Inc. Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology
Lakewood-Amedex Inc. to Present Data on Bisphosphocin™ Nu-3 Bacteriacidal Effect on Bacteria Established in Biofilm at the ICAAC Conference
Lakewood-Amedex Inc. Announces Its Novel Bisphosphocin Class of Antimicrobials are Active Against NDM-1 Positive Bacterial Strains
Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome